CUE Oct 2024 2.000 call
| Previous close | 0.2500 |
| Open | 0.1500 |
| Bid | 0.1500 |
| Ask | 0.5500 |
| Strike | 2.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.1500 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.46k |
GlobeNewswireCue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA® (pembrolizumab)Median overall survival (mOS) of 20.8 months in second line (2L) and beyond HPV+ HNSCC patients treated with CUE-101 monotherapy compared with historical mOS of 7.5 and 8.4 months for third-party checkpoint inhibitor trials in 2L R/M HNSCC: CheckMate 141 and KEYNOTE-040CUE-10
- GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor conferences this June, the Jefferies Global Healthcare Conference, to be held in New York, NY, June 4-6 and the Oppenheimer Novel Targets and Immunology Summit, to be held in New York, NY on June 24. Cue Biopharm
Simply Wall St.Cue Biopharma First Quarter 2024 Earnings: Beats Expectations
Cue Biopharma ( NASDAQ:CUE ) First Quarter 2024 Results Key Financial Results Revenue: US$1.72m (up by US$1.53m from 1Q...
